NL-OMON28411已完成不适用
A randomized phase III study of chimeric anti-CD20 monoclonal antibody (Rituximab) with 2-weekly CHOP chemotherapy (CHOP 14) in elderly patients with intermediate- or high-risk non-Hodgkin’s lymphoma.
Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl0 个研究点目标入组 400 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 400
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients with a confirmed histologic diagnosis of NHL according to the WHO classification: Mantle cell lymphoma (MCL), Follicular lymphoma (grade III) (FL III) or Diffuse large B-cell lymphoma (DLBCL);
- •2. Low-intermediate, high-intermediate or high risk NHL according to age-adjusted IPI score;
排除标准
- •1. Intolerance of exogenous protein administration;
- •2. Severe cardiac dysfunction (NYHA classification II-IV) or LVEF < 45 %;
研究者
相似试验
已完成
3 期
A randomised phase III study of chimeric anti-CD20 monoclonal antibody (rituximab) with two-weekly CHOP chemotherapy (CHOP 14) in elderly patients with intermediate or high-risk non-Hodgkin?s lymphomaon Hodgkin's Lymphoma (NHL)LymphomaCancerISRCTN84611849Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)400
进行中（未招募）
1 期
Phase I/II Study combining humanised anti-CD20 (veltuzumab), anti-CD22 (epratuzumab) and both monoclonal antibodies with chemotherapy in adults with recurrent B precursor acute lymphoblastic leukaemia (ALL)- MARALL - Monoclonal Antibodies In Recurrent B cell ALL (MARALL)This is a phase I/ II trial to determine the efficacy of intravenous veltuzumab and epratuzmab either individually or together in combination with chemotherapy in patients with recurrent acute lymphoblastic lymphoma.MedDRA version: 9.1 Level: LLT Classification code 10003890 Term: B precursor type acute leukaemiaMedDRA version: 9.1 Level: LLT Classification code 10003917 Term: B-cell type acute leukaemiaEUCTR2008-002286-32-GBQueen Mary Medical University of London27
已完成
1 期
Safety and tolerability of the combination of veltuzumab and epratuzumab with intensive chemotherapy in patients with relapsed B-cell acute lymphoblastic leukaemia (ALL)CancerISRCTN15257573Queen Mary University of London27
进行中（未招募）
1 期
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic LeukemiaCD19 PositiveCD20 PositiveRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaRefractory Mantle Cell LymphomaRefractory Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRefractory Small Lymphocytic LymphomaNCT04007029Jonsson Comprehensive Cancer Center24
进行中（未招募）
1 期
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin LymphomaB-cell Non-Hodgkin LymphomaNCT06464185Institute of Hematology & Blood Diseases Hospital, China53